|
16.4.2018 |
EN |
Official Journal of the European Union |
C 134/19 |
Judgment of the General Court of 27 February 2018 — Hansen Medical v EUIPO — Covidien (MAGELLAN)
(Case T-222/16) (1)
((EU trade mark - Revocation proceedings - EU word mark MAGELLAN - Genuine use - Burden of proof - Article 15 and Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 18 and Article 58(1)(a) of Regulation (EU) 2017/1001) - Procedural irregularity committed by the Cancellation Division - Obligation to state reasons - Article 75 of Regulation No 207/2009 (now Article 94 of Regulation 2017/1001) - Oral proceedings - Article 77 of Regulation No 207/2009 (now Article 96 of Regulation 2017/1001)))
(2018/C 134/25)
Language of the case: English
Parties
Applicant: Hansen Medical, Inc. (Mountain View, California, United States) (represented by: R. Kunze, G. Würtenberger and T. Wittmann, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Gája and by D. Walicka, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Covidien AG (Neuhausen am Rheinfall, Switzerland) (represented by: R. Ingerl and D. Wiedemann, lawyers)
Re:
Action brought against the decision of the Second Board of Appeal of EUIPO of 3 February 2016 (Cases R 3092/2014-2 and R 3118/2014-2), relating to revocation proceedings between Hansen Medical and Covidien.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Hansen Medical, Inc. to pay the costs. |